Ladies and gentlemen, thank you all for standing by, and welcome to Quarter Two 2013 China Pharma Holdings’ Earnings Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. (Operator Instructions) I must advise you that this conference is being recorded on Thursday, the 15th of August 2013. I would now like to hand the conference over to your speaker for today, Ms. Diana Huang. Please go ahead.

Thank you, Willy. Good morning ladies and gentlemen, and good evening to those of you joining us from China. Welcome to China Pharma Holdings’ second quarter 2013 earnings conference call. I am Diana Huang, the company’s Investor Relations Manager. Speaking on the call today are China Pharma’s President and CEO and Interim CFO, Ms. Zhilin Li and Corporate Vice President, Mr. Sam Hsing. In addition, I will provide translation during the Q&A session of the call. The company’s earnings press release issued earlier this morning is available on our website at www.chinapharmaholdings.com. I would like to remind our listeners that on this call management’s prepared remarks contain forward-looking statements, which are subject to risks and uncertainties and management may make additional forward-looking statements in response to your questions. Therefore, the company claims the protection of the Safe Harbor forward-looking statements that is contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from those discussed today due to such risks as market and customer acceptance and demand for our products, our ability to market our product, the impact of competitive products and the pricing, the ability to develop and launch new products on a timely basis, the regulatory environment including government regulation in the PRC; our ability to obtain the requisite regulatory approvals to commercialize our products, fluctuations in operating results including spending for research and development and sales and marketing activities, and other risks detailed from time-to-time in our filings with the SEC. In addition, any projections as to the company’s future performance represent management’s estimates as of today August 15, 2013. China Pharma assumes no obligation to update those projections in the future as market conditions change. Now, it is my pleasure to turn the call over to China Pharma’s CEO and Interim CFO, Ms. Li to make her opening remarks in Chinese which will be then translated by Sam. Afterwards, Sam will continue translating Ms. Li’s detailed discussion of the company’s second quarter 2013 financial results.

[Foreign language] Thank you, Diana and good morning everyone. I would like to thank each of you for joining us today and for your continued support of China Pharma. In the second quarter of 2013, we continue to execute our prudent marketing strategy to a more stringent screening of existing and potential distributors and hospital customers in terms of speed of payment in order to gradually improve our trade pattern, especially in terms of the collection of our accounts receivable. This strategy temporarily impacts our sales in the current period. Meanwhile, we entered an eight year construction loan facility with a bank on June 21st, 2013. The total loan facility amount is RMB 80 million approximately U.S. $13 million, and the advance is being used to fund construction of our new GMP upgrading project. We already completed the overall architectural structure of our new GMP facility; and are progressing according to our plan to continue to construct the new facility and ancillary projects. With the support from bank loan, we are more confident that the new GMP upgrading will be accomplished in good quality. I will now read results from Ms. Li's prepared remarks in English. The Chinese pharmaceutical industry has been a key contributor to the PRCs economic growth. China pharmaceutical market reached CNY 926.1 billion in 2012 according to Medicine Blue Book, China Pharmaceutical March Report 2012, Blue Book published by Chinese Academy of Social Science, CASS on December 28, 2012. The Blue Book forecasted that this will continue its rapid expansion at an average rate of the 12% from 2013 to 2010. And pointed out that Chinese pharmaceutical market showing features of rapid expansion, fierce competition, lower concentration and the greatly influenced by government's policies. And the pharmaceutical market expansion is supported by increased demand from medicine…

(Operator Instructions) Your first question comes from Peter Cyrus. Please go ahead.

Peter Cyrus, Hello?

Hi Peter.

Yeah. What's happening with the new drug, we haven't heard any about the any of the new drugs? Can you just update us on those?

[Foreign Language]

To answer your question Ms. Li explained that as for our hot notch product in the clinic trial stage and they are all deal in profit because the government CFDA right of new requirements from time to time and the clinic trial. Therefore that deals in a profit. And secondly Ms. Li mentioned that for the Candesartan which has already received the CFDA product approval. We have succeeding to pass all the [Technical Difficulty] expect to launch these products in the near future.

Right, thank you.

(Operator Instructions) As there are no further questions, I would now like to hand conference over to your speaker for today. Thank you.

On behalf of the entire China Pharma team, we would like to thank you for your interest in the company and the participation on this call. For any of you traveling to China, we always welcome and encourage any visitors from our shareholders, potential investors and analysts. This concludes China Pharma’s second quarter 2013 earnings call. Thanks.

Ladies and gentlemen, that does conclude our conference for today. Thank you all for your participation. You may all disconnect.